Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis by Chin, Calvin W L et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Myocardial Fibrosis and Cardiac Decompensation in Aortic
Stenosis
Citation for published version:
Chin, CWL, Everett, R, Kwiecinski, J, Vesey, AT, Yeung, E, Esson, G, Jenkins, W, Koo, M, Mirsadraee, S,
White, AC, Japp, AG, Prasad, SK, Semple, S, Newby, DE & Dweck, MR 2016, 'Myocardial Fibrosis and
Cardiac Decompensation in Aortic Stenosis', JACC. Cardiovascular imaging.
https://doi.org/10.1016/j.jcmg.2016.10.007
Digital Object Identifier (DOI):
10.1016/j.jcmg.2016.10.007
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
JACC. Cardiovascular imaging
Publisher Rights Statement:
    Open Access funded by British Heart Foundation
    Under a Creative Commons license
J A C C : CARDI O V A SC U LAR IMAGI NG VOL . -, NO. -, 2016
ª 2 0 1 6 B Y T HE AM E R I C AN C O LL EGE OF CAR D IOLOGY FOUNDAT ION. P UB L I SHE D B Y
E L S E V I E R . T H I S I S AN OP EN AC CE S S AR T IC L E UND E R TH E C C B Y L IC ENS E
( h t t p : / / c r e a t i v e c o m m o n s . o r g / l i c e n s e s / b y / 4 . 0 / ) .
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
J A C C : C A R D I O V A S C U L A R I M A G I N G VO L . - , N O . - , 2 0 1 6
ª 2 0 1 6 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O UN DA T I O N . P U B L I S H E D B Y
E L S E V I E R . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R T H E C C B Y L I C E N S E
( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y / 4 . 0 / ) .
I S S N 1 9 3 6 - 8 7 8 X
h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 6 . 1 0 . 0 0 7Myocardial Fibrosis and Cardiac
Decompensation in Aortic Stenosis
Calvin W.L. Chin, MD,a,b Russell J. Everett, MD,a Jacek Kwiecinski, MD,a,c Alex T. Vesey, MD, PHD,a Emily Yeung,a
Gavin Esson,a William Jenkins, MD,a Maria Koo,a Saeed Mirsadraee, MD,a Audrey C. White,a Alan G. Japp, MD, PHD,a
Sanjay K. Prasad, MD,d Scott Semple, PHD,e David E. Newby, MD, PHD,a Marc R. Dweck, MD, PHDaABSTRACTFro
Ca
Sci
Un
of
310
20
be
con
MaOBJECTIVES Cardiac magnetic resonance (CMR) was used to investigate the extracellular compartment and myocardial
fibrosis in patients with aortic stenosis, as well as their association with other measures of left ventricular decompen-
sation and mortality.
BACKGROUND Progressive myocardial fibrosis drives the transition from hypertrophy to heart failure in aortic stenosis.
Diffuse fibrosis is associated with extracellular volume expansion that is detectable by T1 mapping, whereas late
gadolinium enhancement (LGE) detects replacement fibrosis.
METHODS In a prospective observational cohort study, 203 subjects (166 with aortic stenosis [69 years; 69% male];
37 healthy volunteers [68 years; 65% male]) underwent comprehensive phenotypic characterization with clinical imaging
and biomarker evaluation. On CMR, we quantified the total extracellular volume of the myocardium indexed to body
surface area (iECV). The iECV upper limit of normal from the control group (22.5 ml/m2) was used to define extracellular
compartment expansion. Areas of replacement mid-wall LGE were also identified. All-cause mortality was determined
during 2.9  0.8 years of follow up.
RESULTS iECV demonstrated a good correlation with diffuse histological fibrosis on myocardial biopsies (r ¼ 0.87;
p < 0.001; n ¼ 11) and was increased in patients with aortic stenosis (23.6  7.2 ml/m2 vs. 16.1  3.2 ml/m2 in
control subjects; p < 0.001). iECV was used together with LGE to categorize patients with normal myocardium
(iECV <22.5 ml/m2; 51% of patients), extracellular expansion (iECV $22.5 ml/m2; 22%), and replacement fibrosis
(presence of mid-wall LGE, 27%). There was evidence of increasing hypertrophy, myocardial injury, diastolic dysfunction,
and longitudinal systolic dysfunction consistent with progressive left ventricular decompensation (all p < 0.05) across
these groups. Moreover, this categorization was of prognostic value with stepwise increases in unadjusted all-cause
mortality (8 deaths/1,000 patient-years vs. 36 deaths/1,000 patient-years vs. 71 deaths/1,000 patient-years,
respectively; p ¼ 0.009).
CONCLUSIONS CMR detects ventricular decompensation in aortic stenosis through the identification of myocardial
extracellular expansion and replacement fibrosis. This holds major promise in tracking myocardial health in valve disease
and for optimizing the timing of valve replacement. (The Role of Myocardial Fibrosis in Patients With Aortic Stenosis;
NCT01755936) (J AmColl Cardiol Img 2016;-:-–-)© 2016 by the American College of Cardiology Foundation. Published
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ABBR EV I A T I ON S
AND ACRONYMS
AVR = aortic valve
replacement
BNP = brain natriuretic peptide
CMR = cardiac magnetic
resonance
cTnI = cardiac troponin I
ECV = extracellular volume
ECG = electrocardiogram
iECV = indexed extracellular
volume
IQR = interquartile range
LGE = late gadolinium
enhancement
LV = left ventricular
LVH = left ventricular
hypertrophy
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2C alcific aortic stenosis is the mostcommon valvular heart conditionin the western world and a major
public health burden (1). In recent years, the
role of left ventricular (LV) remodeling in dis-
ease progression, symptom development,
and adverse cardiovascular events in aortic
stenosis has been increasingly appreciated
(2). In the initial phases, the increased after-
load imposed by aortic valve narrowing in-
duces adaptive left ventricular hypertrophy
(LVH) that acts to maintain wall stress and
cardiac output. Ultimately, this process de-
compensates, and patients transition from
hypertrophy to heart failure and the develop-
ment of symptoms and adverse cardiovascu-
lar events (2,3). This transition often
correlates poorly with the severity of aortic
valve narrowing and is predominantly drivenby myocardial fibrosis and myocyte cell death (4),
which is perhaps a consequence of supply–demand
mismatch and myocardial ischemia in the hypertro-
phied myocardium (2). Therefore, there is consider-
able interest in developing novel biomarkers to
detect the early signs of LV decompensation.
Cardiac magnetic resonance imaging (CMR) pro-
vides the noninvasive gold standard method for
measuring LV wall thickness, mass, volumes, and
ejection fraction. Moreover, it is able to detect struc-
tural changes in the LV myocardium, including
replacement fibrosis with the late gadolinium tech-
nique and expansion of the extracellular volume using
T1 mapping (5). The latter in part reflects increases in
diffuse myocardial fibrosis (a reversible early form of
fibrosis) (6) and potential changes in the intravascular
compartment. Early studies have suggested that CMR-
derived measures of LV mass and replacement
myocardial fibrosis are of prognostic significance (7,8).
However, these studies have largely been conducted in
small cohorts of patients with end-stage aortic stenosis
who were referred to CMR on clinical grounds. There-
fore, these findings may have been confounded by
referral bias, which limited their applicability and
generalizability to the broad population of patients
with aortic stenosis. Moreover, comparisons with age-
and sex-matched control populations and prognostic
T1 mapping studies have been lacking.
We report the largest prospective study to evaluate
systematically the usefulness of CMR in patients with
aortic stenosis. In particular, we investigated its
ability to detect expansion of extracellular volume
(ECV) and replacement myocardial fibrosis, and how
these are related to other markers of LV decompen-
sation, functional capacity, and clinical outcomes.METHODS
STUDY POPULATION. All stable patients with at least
mild aortic stenosis (aortic jet velocity $2 m/s) who
attended the Edinburgh Heart Centre between March
2012 and August 2014 were invited to participate in
this prospective observational cohort study. The
exclusion criteria were other forms of valvular heart
disease ($ moderate severity), significant co-
morbidities with limited life expectancy, contraindi-
cations to gadolinium-enhanced CMR, and acquired
or inherited nonischemic cardiomyopathies (as
assessed by clinical history or ultimately by CMR). In
addition, we recruited healthy volunteers from the
community with similar demographic characteristics
in terms of age and sex, but no history or clinical
features consistent with current cardiovascular dis-
ease. The study was conducted in accordance with
the Declaration of Helsinki and approved by the local
research committee. Written informed consent was
obtained from all participants.
SUBJECT CHARACTERIZATION. All subjects under-
went detailed clinical evaluation including history,
physical examination, and electrocardiography. In
addition, venous blood samples were obtained for
evaluation of biochemistry and cardiac biomarkers of
interest.
Cardiac biomarkers. Plasma cardiac troponin I concen-
trations (cTnI) were determined by the ARCHITECT
STAT high-sensitivity cTnI assay (Abbot Laboratories,
Abbott Park, Illinois) (9). The brain natriuretic peptide
(BNP) concentration was determined with Triage BNP
assay (Biosite Inc., San Diego, California).
6-min walk test. A 6-min walk test was performed in
156 (94%) patients as an objective measure of func-
tional capacity in our predominantly older adult
cohort, many of whom could not perform an exercise
tolerance test. Explicit instructions were given to
patients asking them to walk as far as possible for
6 min.
Echocardiography. Comprehensive transthoracic echo-
cardiography was performed in all patients (iE33,
Philips Medical Systems, the Netherlands) by a dedi-
cated research ultrasonographer (A.C.W.) and a
cardiologist certified in echocardiography (C.W.L.C.).
The severity of aortic stenosis and diastolic
function were assessed according to American
Society of Echocardiography (ASE) guidelines (Online
Appendix).
Cardiac magnetic resonance. CMR was performed using
a 3-T scanner (MAGNETOM Verio, Siemens AG,
Erlangen, Germany). Short-axis cine images were ac-
quired and used to calculate ventricular volumes,
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3mass, and function. Left ventricular hypertrophy
(LVH) was defined as LV mass (indexed to body sur-
face area using the Du Bois formula) >95th percentile
using age- and sex-specific reference ranges (10). LV
longitudinal function was determined by measuring
the difference in mitral annular displacement be-
tween end-systole and end-diastole (Online
Appendix).
Focal replacement fibrosis and ECV expansion
were assessed in all patients using late gadolinium
enhancement (LGE) and myocardial T1 mapping,
respectively. LGE was performed 15 min after
administration of 0.1 mmol/kg of gadobutrol
(Gadovist, Bayer Pharma AG, Barmen, Germany). The
presence of mid-wall myocardial fibrosis was deter-
mined qualitatively by 2 independent and experi-
enced operators (M.R.D. and C.W.L.C.), and its
distribution was recorded (7,9).
T1 mapping was performed using the Modified
Look-Locker Inversion recovery (11) and a standard-
ized image analysis approach (12). In the short-axis
mid-cavity myocardium, 6 standard segments were
defined onnative T1maps, and these regionswere then
copied onto the corresponding 20-min post-contrast
maps (OsiriX version 4.1.1, Geneva, Switzerland).
Analysis of mid-ventricle segments has been shown to
correlate well with analysis of all 17 myocardial seg-
ments, is simpler to perform, and avoids partial vol-
ume effects in apical segments (12). Segments with
mid-wall LGE present were included in this analysis,
whereas segments that contained subendocardial,
infarct-pattern LGE were excluded. Four commonly
used T1 approaches were assessed: native and
post-contrast myocardial T1, partition coefficient
(lambda), and the ECV fraction. We recently reported
the reproducibility of these measures at 3-T (12).
We also investigated a novel marker, the indexed
extracellular volume (iECV), which modifies the ECV
fraction to act as a measure of the total volume of the
extracellular compartment in the left ventricle. It was
derived using the formula: ECV fraction  LV end-
diastolic myocardial volume normalized to the body
surface area.
HISTOLOGICAL VALIDATION OF MYOCARDIAL
FIBROSIS. All patients who underwent surgical aortic
valve replacement were approached regarding intra-
operative myocardial biopsy at the time of surgery.
Biopsies were obtained from the basal muscular
septum 2 cm below the outflow tract using a Tru-Cut
needle (Carefusion, Vernon Hills, Illinois), and then
were stained with picrosirius red and analyzed using
an automated segmentation tool (Online Appendix).
Two blinded and independent observers (A.T.V. andG.E.) analyzed all the specimens, and the interob-
server reproducibility was 4.1  2.6%.
CLINICAL OUTCOMES. We examined the prognostic
value of the different patterns of fibrosis on all-cause
mortality as our primary outcome. Patients were fol-
lowed between March 2012 and September 2015. All
deaths were identified through the General Register
of Scotland. We also assessed aortic stenosis–related
mortality. This was established from the official death
certificate and defined as any death in which aortic
stenosis was listed as either the primary cause or a
contributing factor to that death by the clinical care
team.
STATISTICAL ANALYSIS. We assessed the distribu-
tion of all continuous variables using the Shapiro-Wilk
test and presented them as mean  SD or median
(interquartile range [IQR]). Comparisons were made
using the 2-sample t test and the Mann-Whitney test
where appropriate. We presented all categorical vari-
ables as percentages and used the chi-square test for
comparison. The relationship between 2 continuous
variables was assessed using either Pearson’s r or
Spearman’s rho, as appropriate. Potential confounders
were adjusted using multivariable linear regression
analyses. Time-to-first event survival curves associ-
ated with the categories of LV decompensation were
estimated using the Kaplan-Meier method and
compared with the log-rank test. All statistical ana-
lyses were performed using SPSS version 20 (IBM,
Armonk, New York) and GraphPad Prism version 6.0
(GraphPad, San Diego, California). A 2-sided p < 0.05
was considered statistically significant.
RESULTS
STUDY POPULATION. A total of 203 subjects were
recruited: 166 patients with aortic stenosis (peak
aortic valve velocity: 3.8  0.90 m/s) and 37 healthy
volunteers. These 2 groups were well matched for
age, sex, chronic renal impairment, and diabetes.
Although a history of hypertension was more com-
mon in the aortic stenosis group, blood pressure was
well-controlled and similar between the 2 groups at
enrollment (Table 1).
LEFT VENTRICULAR HYPERTROPHY. Although the
severity of aortic stenosis correlated positively with
LVH (LV mass index: r ¼ 0.48; p < 0.001), it accounted
for less than one-quarter (r2 ¼ 0.23) of the variance
observed (Figure 1). Male sex and aortic stenosis
severity were the only independent predictors of LV
mass (p < 0.001 for both), independent of systolic
blood pressure, age, and coronary artery disease
status.
TABLE 1 Baseline Characteristics of Patients With Aortic Stenosis and Healthy Volunteers
Healthy Volunteers (n ¼ 37) Aortic Stenosis (n ¼ 166) p Value
Age, yrs 68 (6374) 69 (6375) 0.44
Men 24 (65) 115 (69) 0.57
Hypertension 10 (27) 112 (67) <0.001
Diabetes mellitus 0 25 (15) —
Coronary artery disease 3 (8) 62 (37) —
Coronary CTA assessment 13 (35) 21 (13) —
Invasive coronary angiography 3 (8) 78 (47) —
Previous PCI 2 (5) 11 (6) —
Previous CABG 0 8 (5) —
Atrial fibrillation 0 4 (2) —
Body mass index, kg/m2 27.0  3.6 28.9  4.8 0.02
Body surface area, m2 1.86  0.16 1.88  0.19 0.54
NYHA functional class
I 36 (97) 74 (45)
II 1 (3) 56 (34) <0.001
III — 32 (19)
IV — 4 (2)
6-min walk test, m 430 (400475) 400 (340450) 0.001
Systolic blood pressure, mm Hg 148  16 151  21 0.53
Biomarkers
High sensitivity troponin I concentration, ng/l 3.1 (1.27.1) 6.6 (3.812.4) <0.001
Brain natriuretic peptide concentration, pg/ml 9.5 (5.120.6) 26.1 (10.754.3) 0.001
Echocardiography
Aortic valve area, cm2 2.4  0.6 1.0  0.4 <0.001
Peak aortic jet velocity, m/s 1.4  0.2 3.8  0.9 <0.001
Mean pressure gradient, mm Hg 4.2  1.4 35  19 <0.001
Dimensionless index 0.71 (0.670.81) 0.26 (0.220.32) <0.001
Valvulo-arterial impedance, mm Hg/ml/m2 4.0 (3.64.7) 4.3 (3.65.1) 0.38
Mean e’, cm/s 7.3 (6.28.1) 5.9 (4.97.5) <0.001
Mean E/e’ ratio 8.5 (7.010.4) 12.6 (10.316.9) <0.001
Mean diastolic dysfunction grade 0.5  0.8 2.0  0.9 <0.001
Cardiac magnetic resonance
EDVi, ml/m2 66 (6080) 69 (6178) 0.52
End-systolic volume (indexed), ml/m2 23 (1929) 23 (1827) 0.40
Stroke volume (indexed), ml/m2 44 (4050) 47 (4054) 0.16
Systolic ejection fraction, % 65 (6268) 67 (6371) 0.02
Longitudinal function, mm 14.8  2.7 12.2  2.9 <0.001
LVMi, g/m2 62 (5471) 88 (7399) <0.001
LVMi/EDVi, g/ml 0.92 (0.840.99) 1.24 (1.041.44) <0.001
Maximal myocardial wall thickness, mm 7.5 (6.88.7) 11.4 (8.814.2) <0.001
Mean myocardial wall thickness, mm 5.6 (5.06.3) 7.4 (6.39.0) <0.001
Indexed left atrial volume, ml/m2 28  11 36  15 0.01
Mid-wall late gadolinium enhancement 0 44 (27) —
Native myocardial T1, ms 1,166  27 1,184  42 0.02
20-min post-contrast myocardial T1, ms 645  51 638  46 0.47
Partition coefficient 0.45  0.02 0.46  0.04 0.06
Extracellular volume fraction, % 26.5  1.3 27.7  2.6 0.005
Fibrosis volume, ml 29.9  7.3 44.4  15.1 <0.0001
Indexed extracellular volume, ml/m2 16.1  3.2 23.6  7.2 <0.0001
Values are median (interquartile range), n (%), or mean  SD. Coronary artery disease was defined by previous myocardial infarction, clinical symptoms of angina with
documented evidence of myocardial ischemia in the absence of severe aortic stenosis, a >50% luminal stenosis in a major epicardial coronary artery or previous coronary
revascularization. All patients with clinical symptoms of angina underwent coronary angiography.
CABG ¼ coronary artery bypass graft; CTA ¼ computed tomography angiography; EDVi ¼ end-diastolic volume (indexed); LVMi ¼ left ventricular mass (index); NYHA ¼ New
York Heart Association; PCI ¼ percutaneous coronary intervention.
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FIGURE 1 Factors Governing the Magnitude of the Hypertrophic Response in Aortic Stenosis
Only a modest correlation between the severity of valve narrowing and the magnitude of the hypertrophic response was observed. The other
predictor of left ventricular (LV) mass index on multivariate analysis was sex, with men having more hypertrophy than women.
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5T1 MAPPING AND EXTRACELLULAR EXPANSION. Myo-
cardial biopsies were obtained in 11 of 37 patients who
underwent surgical aortic valve replacement. Strong
correlations were observed between the amount of
myocardial fibrosis on histology and T1 mapping
parameters (native T1: r ¼ 0.76; p ¼ 0.007; lambda:
r ¼ 0.82; p ¼ 0.002; ECV fraction: r ¼ 0.70; p ¼ 0.016;
and iECV: r ¼ 0.87; p < 0.001) (Figure 2), with the
exception of post-contrast myocardial T1 (r ¼ 0.01;
p ¼ 0.98). Indexed LV mass also correlated well with
histological fibrosis (r ¼ 0.83; p < 0.001).
Compared with the healthy volunteers, patients
with aortic stenosis had increased diffuse myocardial
fibrosis, with iECV providing the best discrimination
between cases and control subjects (23.6  7.2 ml/m2
vs. 16.1  3.2 ml/m2; p < 0.0001) (Table 1 and Figure 2).
Moreover, of all the T1 measures, only the iECVdemonstrated a progressive increase across patients
with mild, moderate, and severe aortic stenosis
(19.6  4.6 ml/m2 vs. 22.9  5.4 ml/m2 vs. 25.5 
8.1 ml/m2, respectively; p < 0.001) (Table 2). Notably,
the ECV fraction did not vary with aortic stenosis
severity (as measured by peak aortic valve velocity;
p ¼ 0.30 (Online Table 1) and showed a high degree
of overlap between cases and control subjects
(26.5  1.4% vs. 27.7  2.6%; p ¼ 0.007).
We explored iECV in greater detail, dividing our
entire patient cohort into tertiles of iECV (Table 3).
Using this approach, a steady increase across the ter-
tiles was observed for each of the following markers of
disease severity and LV decompensation: indexed LV
mass, peak aortic valve velocity, plasma high-
sensitivity cTnI concentrations, serum BNP concen-
trations, diastolic dysfunction, longitudinal systolic
FIGURE 2 iECV as a Marker of Extracellular Expansion in the Myocardium
(A) Regions of interest manually drawn onto native and post-contrast T1 maps are used to calculate indexed extracellular volume (iECV). (B)
Histology from a patient with aortic stenosis (AS) with areas of diffuse fibrosis stained with picrosirus red. (C) Excellent correlation between
iECV and diffuse myocardial fibrosis on histology. (D) iECV provided good discrimination between disease states. (E) iECV values were higher in
patients with replacement fibrosis than patients with normal myocardium or extracellular expansion.
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6dysfunction, and the proportion of patients with mid-
wall fibrosis (p < 0.05 for all). Similar results were
obtained using tertiles of the ECV fraction (Online
Table 1), but by comparison, tertiles of LV mass index
were less discriminatory, with no differences in dia-
stolic function nor in serum BNP concentrations across
these groups (both p > 0.05) (Online Table 2).REPLACEMENT MYOCARDIAL FIBROSIS. Replace-
ment mid-wall fibrosis, as assessed by LGE, was pre-
sent in 44 (27%) patients with aortic stenosis but in
none of the healthy volunteers. We examined the as-
sociation between mid-wall myocardial fibrosis and
the severity of aortic stenosis (Table 2). Although pa-
tients with mid-wall fibrosis had more severe aortic
TABLE 2 Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis and Functional Status by Severity of Aortic Stenosis
Mild (n ¼ 34) Moderate (n ¼ 45) Severe (n ¼ 87) p Value
Age, yrs 67 (5675) 72 (6677) 71 (6576) 0.048
Men 20 (59) 32 (71) 63 (72) 0.33
EDVi, ml/m2 69 (6077) 68 (6481) 69 (6179) 0.72
End-systolic volume (indexed), ml/m2 24 (1926) 23 (2027) 22 (1727) 0.87
Stroke volume (indexed), ml/m2 47 (3952) 47 (4256) 47 (4054) 0.56
Systolic ejection fraction, % 67 (6369) 66 (6370) 67 (6372) 0.65
Longitudinal function, mm 13.6  2.4 13.2  2.9 11.2  2.8 <0.001
LVMi, g/m2 71 (6186) 87 (7498) 93 (80104) <0.001
LVMi/EDVi, g/ml 1.08  0.20 1.21  0.23 1.36  0.28 <0.001
Maximal myocardial wall thickness, mm 8.2  2.1 11.1  3.3 13.4  3.4 <0.001
Mean myocardial wall thickness, mm 5.9  1.1 7.3  1.6 8.7  1.9 <0.001
Patients with LVH 6 (17) 24 (53) 59 (68) <0.001
Native myocardial T1, ms 1,170  30 1,180  37 1,192  46 0.02
20-min post-contrast myocardial T1, ms 637  45 643  48 636  45 0.73
Partition coefficient 0.466  0.03 0.466  0.04 0.466  0.05 0.07
ECV fraction, % 27.8  2.5 27.5  2.0 27.8  3.0 0.79
iECV, ml/m2 19.6  4.6 22.9  5.4 25.5  8.1 <0.001
Extracellular expansion (iECV $22.5 ml/m2) 9 (26) 23 (51) 47 (54) 0.021
Mid-wall late gadolinium enhancement 2 (5.9) 14 (31) 28 (32) 0.008
Diastolic function (E/e’) 11.1 (8.014.2) 12.2 (10.116.4) 13.5 (11.418.6) 0.009
Natural log (hs troponin I) 1.25 (0.721.55) 1.76 (1.332.34) 2.16 (1.592.81) <0.0001
6-min walk test, m 420 (363448) 400 (340450) 390 (320440) 0.05
Values are median (interquartile range), n (%), or mean  SD.
ECV ¼ extracellular volume; LVH ¼ left ventricular hypertrophy; other abbreviations as in Tables 1 and 2.
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7stenosis compared with those without (peak aortic
valve velocity: 4.1 m/s; IQR: 3.7 to 4.6 m/s vs. 3.8 m/s;
IQR: 3.4 to 4.6 m/s, respectively; p ¼ 0.001), this dif-
ference was small and unlikely to be of any clinical
significance. In contrast, patients with mid-wall
fibrosis demonstrated a marked 30% increase in LV
mass indicative of an advanced hypertrophic response
(LV mass index 107  24 g/m2 vs. 82  16 g/m2,
respectively; p < 0.001). LV mass index was inde-
pendently associated with mid-wall myocardial
fibrosis in those with hypertrophy (odds ratio: 1.09,
95% confidence interval: 1.04 to 1.14; p < 0.001) after
adjusting for aortic stenosis severity, age, sex, and
systolic blood pressure.
RELATIONSHIP BETWEEN MYOCARDIAL ECV AND
REPLACEMENT FIBROSIS. It has been suggested that
replacement fibrosis represents the irreversible final
stage of diffuse interstitial fibrosis and extracellular
expansion. Consistent with this hypothesis, patients
with replacement mid-wall fibrosis had evidence of
increased ECV on T1 mapping compared with patients
without (iECV: 32.0 ml/m2; IQR: 29.1 to 34.9 ml/m2 vs.
21.5 ml/m2; IQR: 20.6 to 22.4 ml/m2; p < 0.0001; ECV
fraction: 29.1  2.4% vs. 26.9  2.1%; p < 0.001). The
iECV was independently associated with mid-wall
fibrosis after adjusting for age, sex, severity of aorticstenosis, and even LV mass (odds ratio: 1.22; 95%
confidence interval: 1.11 to 1.35; p < 0.001). Similar
associations were observed using the ECV fraction.
CATEGORIZATION OF LV DECOMPENSATION. We
proceeded to categorize patients into 3 groups ac-
cording to our CMR measures of myocardial fibrosis:
normal myocardium, extracellular expansion, and
replacement mid-wall fibrosis (Figure 3). The upper
limit of normal for iECV in the healthy volunteers
(defined by 2 SDs above the mean, 22.5 ml/m2) was
used to define expansion of the extracellular
myocardium. Values below this threshold defined
normal myocardium. This categorization was then
validated in the 11 patients who underwent myocar-
dial biopsy, with the percentage fibrosis on histology
increasing progressively across the 3 groups (normal
myocardium: 8.9  4.0% vs. extracellular expansion:
12.4  2.5% vs. replacement fibrosis: 22.4  4.9%;
p < 0.004) (Table 4).
In the larger imaging cohort of patients with aortic
stenosis (after exclusion of patients with an infarct
pattern of LGE, n ¼ 22, or incomplete T1 mapping
data, n ¼ 5), 71 patients had normal myocardium
(iECV <22.5 ml/m2). These patients had largely
mild-to-moderate aortic stenosis, a mild hypertro-
phic response, minimal cardiac injury, and good
TABLE 3 Progressive Increase in Markers of LV Hypertrophy and Decompensation With Increasing iECV Stratified Into Tertiles
Tertile 1 (n ¼ 54) Tertile 2 (n ¼ 54) Tertile 3 (n ¼ 53) p Value
Age, yrs 70 (6375) 70 (6570) 72 (6478) 0.30
Men 27 (50) 42 (78) 43 (81) 0.0006
Echocardiography
Peak aortic jet velocity, m/s 3.45  0.78 3.77  0.81 4.25  0.96 <0.0001
Aortic valve area, cm2 1.01  0.37 0.95  0.36 0.90  0.35 0.32
Mean AV pressure gradient, mm Hg 27.6 12.7 32.7  15.0 42.6  23.7 <0.0001
Mild aortic stenosis 19 12 3
Moderate aortic stenosis 13 17 15
Severe aortic stenosis 22 25 35
Valvulo-arterial impedance, mm Hg/ml/m2 4.4  1.1 4.0  1.0 3.8  1.0 0.019
Mean e’, cm/s 6.9  2.0 6.4  1.7 5.4  1.8 <0.0001
Mean E/e’ ratio 11.6 (9.814.4) 12.4 (9.316.5) 14.3 (11.919.2) 0.02
Mean diastolic dysfunction grade 1.5  1.0 2.0  0.8 2.5  0.7 <0.0001
CMR
LVMi, g/m2 68  9 88  9 110  19 <0.0001
Ejection fraction, % 68 (6371) 67 (6473) 66 (6171) 0.44
Longitudinal function, mm 13.0  2.7 12.8  2.7 11.0  3.0 0.0004
Mid-wall fibrosis 2 (4) 6 (11) 36 (68) 0.0001
Indexed left atrial volume, ml/m2 29  13 36  14 38  13 0.004
Biomarkers
Natural log (hs troponin I) 1.3 (0.81.6) 2.1 (1.5–2.4) 2.5 (1.93.3) <0.0001
Natural log (BNP) 2.8 (1.93.5) 3.1 (2.43.9) 4.0 (2.84.7) <0.0001
Functional status
6-min walk test, m 410 (345445) 410 (358453) 385 (295443) 0.09
NYHA functional class, %
I 27 (50) 23 (43) 24 (45)
II 20 (37) 19 (35) 15 (28)
III 6 (11) 12 (22) 11 (21)
IV 1 (2) 0 (0) 3 (6)
Outcomes
All-cause mortality 2 2 10 —
Mortality rate (per 1,000 patient-years) 12 12 72 0.005
Aortic stenosisrelated mortality 0 2 8 —
Values are median (interquartile range), n (%), or mean  SD. Five patients had insufficient data to calculate the indexed extracellular volume.
AV ¼ aortic valve; BNP ¼ brain natriuretic peptide; CMR ¼ cardiac magnetic resonance; hs ¼ high-sensitivity; other abbreviations as in Table 1.
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Thirty-one patients had extracellular expansion
(iECV $22.5 ml/m2), with values for aortic stenosis
severity, LV mass, myocardial injury, diastolic func-
tion, and longitudinal systolic function that were in-
termediate between patientswith normalmyocardium
and replacement fibrosis. Finally, 37 patients had evi-
dence of replacement myocardial fibrosis on LGE.
These patients were confirmed as having the most se-
vere aortic stenosis, LVH, myocardial injury, and
impairment in LV performance (Table 4). Compared
with patients with extracellular expansion, they had
even higher iECV values (30.4  8.2 ml/m2 vs. 25.4 
3.1 ml/m2; p < 0.0001) (Figure 2), whereas compared
with patients with normal myocardium, they had
increased serum BNP concentrations (16.7 pg/ml; IQR:
6.1 to 36.0 pg/ml vs. 34.4 pg/ml; IQR: 10.5 to 76.2 pg/ml,respectively, p ¼ 0.026) and impaired functional ca-
pacity (6-min walk test: 405  74 m vs. 359  138 m,
respectively; p ¼ 0.03). Both mid-wall fibrosis and the
ECV fraction were predictors of functional capacity
independent of age, sex, LV mass, and peak velocity
(Table 5). These findings were unchanged when pa-
tients withmild aortic stenosis were excluded from the
analysis (Online Table 3).
CLINICAL OUTCOMES. Participants were followed up
for an average of 2.9  0.8 years during which a total
of 14 patients with aortic stenosis died: 2 with normal
myocardium, 4 with extracellular expansion and 8
with replacement fibrosis. Unadjusted all-cause
mortality rates rose progressively across the groups
(8 deaths/1,000 patient-years vs. 36 deaths/1,000
patient-years vs. 71 deaths/1,000 patient-years;
FIGURE 3 CMR Categorization of Myocardial Fibrosis in Aortic Stenosis
Patients with aortic stenosis were categorized into 3 groups based upon cardiac magnetic resonance (CMR) assessments of fibrosis.
iECV ¼ indexed extracellular volume; LGE ¼ late gadolinium enhancement.
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9log-rank test: p ¼ 0.009 (Table 4, Figure 4). AS-related
mortality also increased in a stepwise fashion
(0 deaths/1,000 patient-years vs. 36 deaths/1,000
patient-years vs. 52 deaths/1,000 patient-years;
p ¼ 0.0045) with no AS-related deaths in the normal
myocardium group. Tertiles of ECV fraction
(p ¼ 0.0006) (Online Table 1) and iECV (p ¼ 0.005)
(Table 3) also displayed prognostic ability in this
unadjusted analysis but no difference in mortality
was observed across tertiles of the indexed LV mass
(p ¼ 0.23) (Online Table 2).
DISCUSSION
This is the largest prospective CMR study to sys-
tematically evaluate both extracellular expansionand replacement fibrosis in the myocardium of
patients with aortic stenosis and healthy control
subjects. Both measures are increased in aortic ste-
nosis, but are only weakly associated with the
severity of valve narrowing. In contrast, they
demonstrate a close association with the magnitude
of the hypertrophic response, the presence of LV
dysfunction, the functional capacity of the patient,
and, ultimately, clinical outcome. We believe these
findings demonstrate that the structural changes in
the LV myocardium are as important a consideration
as the severity of the valvular disease itself. Based on
these results, we propose that patients with aortic
stenosis be categorized into 3 groups—those with
normal myocardium, extracellular expansion, and
replacement myocardial fibrosis. We believe this
TABLE 4 Characteristics of Patients Stratified According to iECV Thresholds and Presence of Mid-Wall Late Gadolinium Enhancement
Normal Myocardium
(n ¼ 71)
Extracellular Expansion
(n ¼ 31)
Replacement Fibrosis
(n ¼ 37) p Value
Age, yrs 70 (6375) 70 (6375) 71 (6578) 0.59
Sex (male ¼ 1) 0.56 (0.440.68) 0.81 (0.670.96) 0.76 (0.620.90) 0.023
Hypertension 48 (68) 20 (65) 22 (59) 0.70
Diabetes 8 (11) 7 (23) 2 (5) 0.09
Body mass index, kg/m2 28.2  4.5 28.9  4.6 29.3  4.3 0.44
Echocardiography
Peak aortic jet velocity, m/s 3.53  0.82 3.79  1.0 4.23  0.92 <0.001
Aortic valve area, cm2 0.98 (0.731.18) 0.88 (1.20.7) 0.83 (0.730.91) 0.049
Mean AV pressure gradient, mm Hg 29.1  14.2 34.8  21.1 41.1  23.5 0.007
Mild AS 24 7 2
Moderate AS 18 10 11
Severe AS 29 14 24
Valvulo-arterial impedance, mm Hg/ml/m2 4.1  1.0 3.9  0.9 4.0  1.0 0.46
Mean e’, cm/s 6.7  2.0 6.5  1.8 5.2  1.4 0.0004
Mean E/e’ ratio 13.1  7.7 13.2  4.8 16.5  6.5 0.04
Mean diastolic dysfunction grade 1.5  0.9 2.0  0.9 2.7  0.5 <0.0001
CMR
LVMi, g/m2 73  11 96  11 107  25 <0.0001
Relative wall thickness 0.60  0.12 0.61  0.09 0.67  0.11 0.018
ECVi, ml/m2 18.3  2.5 25.4  3.1 30.4  8.2 <0.0001
Ejection fraction, % 68 (6371) 66 (6471) 67 (6472) 0.94
Longitudinal systolic function, mm 13.2  2.6 12.5  2.4 11.2  3.1 0.002
Indexed left atrial volume, ml/m2 31  13 37  11 38  15 0.027
Biomarkers
Natural log (hs troponin I) 1.43  0.96 2.02  0.93 2.60  0.90 <0.0001
Natural log (BNP) 2.95  1.00 3.06  0.96 3.41  1.10 0.12
Functional status
6-min walk test, m 406  74 38595 359  138 0.08
NYHA functional class
I 33 (46) 18 (58) 17 (46)
II 27 (38) 6 (19) 12 (32)
III 11 (15) 7 (23) 5 (14)
IV 0 (0) 0 (0) 3 (8)
Outcomes
All-cause mortality 2 4 8 —
All-cause mortality rate (per 1,000 patient- years) 8 36 71 0.009
AS-related mortality, n 0 4 6 —
AS-related mortality rate (per 1,000 patient-years) 0 36 52 0.0045
Patients Undergoing
Myocardial Biopsy
Normal Myocardium
on CMR (n ¼ 3)
Extracellular
Expansion on CMR (n ¼ 5)
Replacement
Fibrosis on CMR (n ¼ 3) p Value
Histological fibrosis, % 8.9  4.0 12.4  2.5 22.4  4.9 0.004
Aortic valve area, cm2 0.57  0.10 0.94  0.29 0.81  0.44 0.29
Peak aortic jet velocity, m/s 4.6 (4.45.1) 4.5 (4.05.9) 4.9 (4.18.0) 0.63
LVMi, g/m2 76  15 98  4 162  6 <0.0001
Native myocardial T1, ms 1,189  23 1,183  16 1,277  15 0.0002
Post-contrast myocardial T1, ms 676  45 615  24 672  84 0.22
Partition coefficient 0.43  0.05 0.47  0.02 0.55  0.02 0.008
ECV fraction, % 25.3  3.1 27.3  1.4 32.2  1.9 0.019
iECV, ml/m2 18.8  1.9 25.6  0.7 49.6  4.8 <0.0001
Values are median (interquartile range), n (%), or mean  SD.
Abbreviations as in Tables 1 to 3.
Chin et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . - , N O . - , 2 0 1 6
Myocardial Fibrosis in AS - 2 0 1 6 :- –-
10
FIGURE 4 Progressive LV Decompensation on Moving From Normal Myocardium to Extracellular Expansion to Replacement Fibrosis
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On moving from normal myocardium to extracellular expansion and then replacement fibrosis, there was a stepwise increase in the following
measures: (A) the severity of valve narrowing; (B) the degree of hypertrophy; (C)myocardial injury; (D) left ventricular (LV) performance; and
(E) all-cause-mortality. hsTni ¼ high-sensitivity troponin I concentration.
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11classification has major potential in the early detec-
tion of subclinical ventricular decompensation in
aortic stenosis and ultimately may be able to guide
decisions regarding the timing of aortic valve
replacement.
Our data demonstrated an association between
the severity of valve narrowing and the degree of
hypertrophy in aortic stenosis. However, this only
explained approximately one-quarter of the
observed variance in LV mass, confirming that the
hypertrophic response in aortic stenosis cannot
be accurately predicted from the degree of valve
narrowing alone and should be assessed
independently.T1 mapping techniques (ECV fraction and iECV) can
provide an assessment of myocardial ECV expansion.
Potentially, this can reflect increased myocardial
fibrosis, myocardial infiltration, or expansion in the
intravascular compartment (13). In aortic stenosis,
myocardial fibrosis has been established pathologi-
cally as a key process that drives the transition from
hypertrophy to heart failure (4). Moreover, we and
others have observed a close correlation between these
parameters and histological assessments of myocar-
dial fibrosis (5,14–16). However, there is some
debate as to whether T1 mapping can provide direct
assessment of the myocardium because of recent evi-
dence that indicated that increased intravascular
TABLE 5 Univariable and Multivariable Linear Regression Analysis to Examine the Association of Fibrosis Assessments With Functional Status
Univariable Analysis Multivariable Analysis
Relative Change in
6-Min Walk (95% CI) p Value
Model 1 (ECV fraction) Model 2 (mid-wall fibrosis)
Relative Change in
6-Min Walk (95% CI) p Value
Relative Change in
6-Min Walk (95% CI) p Value
Age $70 yrs 50.3 (83.0 to 17.6) 0.003 41.4 (74.5 to 8.36) 0.01 50.3 (83.0 to 17.7) 0.003
Men 0.81 (37.7 to 36.1) 0.97 19.9 (61.3 to 21.6) 0.35 8.88 (48.5 to 30.7) 0.66
Peak aortic jet velocity, m/s 12.25 (30.6 to 6.14) 0.19 14.9 (35.4 to 5.73) 0.16 11.9 (32.4 to 8.64) 0.26
LVMi, g/m2 0.22 (1.00 to 0.56) 0.57 0.62 (0.44 to 1.68) 0.25 0.45 (0.62 to 1.52) 0.41
ECV fraction, % 9.09 (15.4 to 2.81) 0.005 9.77 (17.0 to 2.58) 0.01 — —
Presence of midwall fibrosis 40.9 (78.5 to 3.24) 0.03 — — 45.6 (89.1 to 2.11) 0.04
CI ¼ confidence interval; other abbreviations as in Tables 2 and 3.
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12volume may also influence native T1 values (17,18).
Pressure overload conditions such as aortic stenosis
are associated with reduced capillary density (19) and
myocardial ischemia (20). Mahmod et al. (17) recently
suggested that this ischemia might result in coronary
vasodilatation and increased intravascular volume
potentially contributing to increased native T1.
Although confirmation of this interesting hypothesis
is required, it may be that T1 values are also related to
myocardial ischemia that is believed to trigger fibrosis
and the transition from hypertrophy to heart failure.
Regardless, T1 mapping remains at the very least a
useful surrogate of myocardial fibrosis and LV
decompensation in aortic stenosis.
Controversy remains as to the optimal T1 image
analysis strategy (12,13,21). Consistent with previous
research (12), both native T1 and the ECV fraction
demonstrated major overlap with values in control
groups and little difference among patients with
mild, moderate, and severe aortic stenosis (Table 2).
We sought to tackle this issue by developing a novel
parameter, the iECV, which provides an assessment
of the total ECV in the myocardium. This effectively
combines the prognostic information provided by the
ECV fraction with the improved discrimination be-
tween groups associated with indexed LV mass into a
single measure (Table 3, Online Tables 1 and 2).
iECV demonstrated good correlation with histolog-
ical assessment of fibrosis burden. Moreover, there
was a clear stepwise increase across tertiles of iECV in
each of the different clinical and imaging measures of
LV decompensation, as well as clinical outcomes,
supporting iECV as a marker of decompensation.
Finally, iECV provided the best discrimination among
disease states, being the only T1 measure to differen-
tiate among patients with mild, moderate, and severe
aortic stenosis. In combination, iECV would therefore
appear to provide the most useful marker of LV
decompensation in aortic stenosis with advantagescompared with both the ECV fraction and LV mass in
isolation.
How do extracellular expansion and diffuse
fibrosis relate to the development of replacement
fibrosis as detected using mid-wall LGE? In agree-
ment with previous studies (7,8), regions of mid-wall
LGE were observed in 27% of our patients, with
approximately two-thirds with severe aortic
stenosis and one-third with moderate aortic stenosis.
Importantly, patients with mid-wall replacement
fibrosis also had marked increases in iECV as a sur-
rogate for diffuse fibrosis in their remote myocar-
dium. Indeed, iECV was an independent predictor of
the presence of mid-wall LGE. This was confirmed
by our histological data and suggests that replace-
ment fibrosis does not occur until the end stages of
myocardial matrix remodeling and is preceded by
an intermediate stage of extracellular expansion
reflecting increasing diffuse fibrosis. Longitudinal
studies using serial CMR imaging are required to
confirm this hypothesis.
Using our CMR assessments, we categorized our
patients into 3 stages of LV decompensation. We
used iECV to differentiate patients with normal
myocardium from those with extracellular expansion
and then LGE to define replacement fibrosis
(Figure 3). Across these groups, patients had
advancing LVH, histological fibrosis, myocyte cell
injury, diastolic dysfunction, and longitudinal sys-
tolic dysfunction, which suggested progressive, sub-
clinical LV decompensation. Most importantly, there
was a steady decline in prognosis, with unadjusted
all-cause mortality rates quadrupling from the normal
myocardium groups to the extracellular expansion
groups and more than doubling again in those with
replacement fibrosis. Moreover, these groups also
predicted aortic stenosisrelated deaths on unad-
justed analysis, with no aortic stenosisrelated
deaths occurring in the normal myocardium group.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Decompensation
of the hypertrophic response in aortic stenosis is driven by pro-
gressive myocardial fibrosis and the associated expansion in the
ECV. Changes in the LV myocardium can be tracked using CMR,
which can be used to categorize patients into 3 groups: normal
myocardium, extracellular expansion, and replacement fibrosis.
There is evidence of increasing myocyte injury, left ventricular
dysfunction, functional impairment, and all-cause mortality
across these groups.
TRANSLATIONAL OUTLOOK: This categorization holds
promise in tracking the transition from hypertrophy to heart
failure in aortic stenosis and in identifying the optimal timing of
aortic valve replacement. Prospective randomized controlled
studies are required to investigate this further.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . - , N O . - , 2 0 1 6 Chin et al.
- 2 0 1 6 :- –- Myocardial Fibrosis in AS
13More simple categorization using LV mass was less
discriminatory and not of prognostic value (Online
Table 2).
Our categorization holds promise as a means of
monitoring the development of LV decompensation
and helping to optimize the timing of aortic valve
replacement. Currently, the development of symp-
toms guides the need for surgery. However, symp-
toms are frequently difficult to assess in older adult
patients with multiple co-morbidities. Objective
imaging assessments that monitor the changes in
myocardial structure that are themselves responsible
for progressive LV decompensation are therefore
potentially attractive (2,3). This is the first study to
describe iECV in aortic stenosis, so that confirmation
of our findings in larger studies with longer follow-up
is required. However, we presented the fourth sepa-
rate cohort to demonstrate the adverse prognosis
associated with mid-wall LGE in aortic stenosis
(7,8,22) and demonstrated its association with
patient functional capacity, LV performance, and
multiple other parameters of LV decompensation.
These data have now led to the EVOLVED (Early
Valve Replacement guided by Biomarkers of Left
Ventricular Decompensation in Asymptomatic Pa-
tients with Advanced Aortic Stenosis) study. This
multicenter, randomized controlled trial will begin
enrollment next year and assess whether early valve
intervention in patients with asymptomatic severe
aortic stenosis and mid-wall fibrosis on CMR im-
proves clinical outcomes compared with standard
care.
STUDY LIMITATIONS. There were insufficient deaths
to perform multivariate analysis. Studies with longer
follow-up are required to confirm whether iECV is of
independent prognostic value and to assess the
contribution of the intravascular volume to T1 map-
ping values. Finally, although similar to previous
studies (14–16), the number of patients who agreed to
intraoperative myocardial biopsy was modest, which
perhaps reflected the invasive nature of this
assessment.CONCLUSIONS
CMR can detect progressive fibrosis in aortic stenosis
and can be used to categorize patients with normal
myocardium, extracellular expansion, or replacement
fibrosis. Across these groups, there was a stepwise in-
crease in myocardial injury, fibrosis, LV dysfunction,
and unadjusted mortality that was consistent with
progressive ventricular decompensation. This catego-
rization may be able to track the transition of hyper-
trophy to heart failure in patients with aortic stenosis.
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